A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis

BACKGROUND: Treatment with nab-paclitaxel with gemcitabine demonstrates a survival advantage when compared with single-agent gemcitabine. However, the combination is associated with significant toxicities, leading to a high rate of drug discontinuation. We implemented a modified regimen of gemcitabi...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Ther Adv Med Oncol
Κύριοι συγγραφείς: Ahn, Daniel H., Krishna, Kavya, Blazer, Marlo, Reardon, Joshua, Wei, Lai, Wu, Christina, Ciombor, Kristen K., Noonan, Anne M., Mikhail, Sameh, Bekaii-Saab, Tanios
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: SAGE Publications 2016
Θέματα:
Original Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5298402/
https://ncbi.nlm.nih.gov/pubmed/28203300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016676011
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια